
News|Articles|February 13, 2019
Daurismo for Newly Diagnosed AML
Author(s)Drew Boxler
Advertisement
Daurismo (glasdegib, Pfizer)
Indications: Newly-diagnosed acute myeloid leukemia (AML) in adult patients who are 75 years old or older and have comorbidities that preclude use of intensive induction chemotherapy
Dosage: 100 mg orally, once daily.
Contraindications: None
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Zepbound Lowers Health Care Costs in Older Adults With Obesity
2
Study Identifies Patients at Risk for Severe COVID-19 Post-Vaccination
3
Ixekizumab, Tirzepatide Maintains Efficacy in Psoriatic Disease
4
Measles Resurgence Exposes US Vaccine Policy Risks, Experts Warn
5






































